Photo of Amy Klobuchar
D United States Senate · Minnesota

Sen. Amy Klobuchar

Compare
Total votes
1,044
all sessions
Attendance
99%
12 missed
Near the chamber average
With party
98%
of cast votes
Higher than 85% of chamber peers
Bipartisan score
1%
crosses aisle rarely
Lower than 87% of chamber peers
Sponsored
2,456
bills & resolutions
Higher than 95% of chamber peers
Committees
18
assignments
2,456 bills and resolutions

Sponsored bills

Total
2,456
Primary
430
Co-sponsor
2,026
This page
2,456
matching current filters
Co-sponsor S 909
In committee · Indiana Senate · Co-sponsor
Prescription Drug Price Relief Act of 2021

Prescription Drug Price Relief Act of 2021 This bill establishes a series of oversight and disclosure requirements relating to the prices of brand-name drugs. Specifically, the bill requires the Department of Health and Human Services (HHS) to review at least annually all brand-name drugs for excessive pricing; HHS must also review prices upon petition. If any such drugs are found to be excessively priced, HHS must (1) void any government-granted exclusivity; (2) issue open, nonexclusive licenses for the drugs; and (3) expedite the review of corresponding applications for generic drugs and biosimilar biological products. HHS must also create a public database with its determinations for each drug. Under the bill, a price is considered excessive if the domestic average manufacturing price exceeds the median price for the drug in Canada, the United Kingdom, Germany, France, and Japan. If a price does not meet this criteria, or if pricing information is unavailable in at least three of the aforementioned countries, the price is still considered excessive if it is higher than reasonable in light of specified factors, including development cost, revenue, and the size of the affected patient population. The bill also requires drug manufacturers to report specified financial information for brand-name drugs, including research and advertising expenditures.

In committee Mar 23, 2021 1 co-sponsor
Primary S 905
In committee · Indiana Senate · Lead sponsor
Freedom To Invest in Tomorrow's Workforce Act

Freedom To Invest in Tomorrow's Workforce Act This bill allows the use of funds in a qualified tuition program (commonly known as a 529 account) to pay for expenses associated with obtaining or maintaining recognized postsecondary credentials.

In committee Mar 23, 2021 0 co-sponsors
Co-sponsor S 901
In committee · Indiana Senate · Co-sponsor
FAIR Proceedings Act

Funding Attorneys for Indigent Removal Proceedings Act or the FAIR Proceedings Act This bill expands access to counsel for aliens in immigration proceedings and provides for protections related to such proceedings. An alien shall have the privilege of being represented by counsel in any immigration proceeding, whereas currently this privilege is statutorily provided for only in removal proceedings. Similarly, the Department of Justice (DOJ) may provide counsel at government expense to aliens in any immigration proceeding, whereas currently DOJ is statutorily authorized to provide counsel to aliens only in removal proceedings and at no expense to the government. Under this bill, DOJ shall provide counsel to children and vulnerable individuals in such proceedings, at government expense if necessary. If DOJ fails to do so, certain limits on filing a motion to reopen removal proceedings (such as the time limit for filing) shall not apply, and the alien's removal shall be stayed upon the motion's filing. The Department of Homeland Security (DHS) shall provide each alien, generally at the beginning of proceedings, a complete copy of the alien's case file in DHS possession, unless the alien waives this right in writing. Failure to provide such documents shall delay the alien's removal proceeding. DHS shall facilitate for all detained aliens access to counsel and programs that inform such aliens of their immigration-related rights and obligations.

In committee Mar 23, 2021 1 co-sponsor
Co-sponsor S 913
In committee · Indiana Senate · Co-sponsor
COVID–19 Disinformation Research and Reporting Act of 2021

COVID-19 Disinformation Research and Reporting Act of 2021 This bill requires the National Science Foundation to contract with the National Academies of Sciences, Engineering, and Medicine to study disinformation and misinformation about COVID-19 (i.e., coronavirus disease 2019) on the internet and social media platforms.

In committee Mar 23, 2021 1 co-sponsor
Co-sponsor S 926
In committee · Indiana Senate · Co-sponsor
SASCA

Survivors' Access to Supportive Care Act or SASCA This bill sets out programs and requirements to address access and quality issues related to sexual-assault examinations. Specifically, the bill establishes training and technical assistance programs for health care providers on conducting sexual-assault examinations and treating survivors of sexual assault, including in rural and tribal settings; grants for states to assess the availability of trained providers to perform sexual-assault examinations; and a task force to assist state-level efforts to improve medical forensic evidence collection related to sexual assault. The bill also requires institutions of higher education to provide information about the availability of sexual-assault examinations to survivors of sexual assault. Additionally, hospitals and specified components of the Department of Health and Human Services (HHS) must report on access and quality issues concerning sexual-assault examinations and related services. Furthermore, HHS must address access to, and the quality of, trained health care providers who conduct sexual-assault examinations in the National Quality Strategy. This is a national effort to align public-sector and private-sector stakeholders to achieve better health and health care.

In committee Mar 23, 2021 1 co-sponsor
Co-sponsor S 936
In committee · Indiana Senate · Co-sponsor
INFORM Consumers Act

Integrity, Notification, and Fairness in Online Retail Marketplaces for Consumers Act or the INFORM Consumers Act This bill requires online marketplaces to collect, verify, and disclose certain information from high-volume, third-party sellers. High-volume, third-party sellers include online marketplace participants that conduct 200 or more transactions resulting in total revenues of $5,000 or more during a continuous 12-month period. Online marketplaces must acquire these sellers' (1) bank account numbers, (2) government-issued identification, (3) tax identification numbers, and (4) contact information. Online marketplaces must verify this information and annually certify any changes to it. Further, online marketplaces must make certain information (e.g., sellers' names and contact information) available to consumers through the sellers' product listings and provide consumers with methods to report electronically and by telephone any suspicious activity on the marketplace. The bill provides the Federal Trade Commission with the authority to enforce these requirements.

In committee Mar 23, 2021 1 co-sponsor
Primary S 902
In committee · Indiana Senate · Lead sponsor
Housing Supply and Affordability Act

Housing Supply and Affordability Act This bill allows the Department of Housing and Urban Development to award grants to states, local governments, Indian tribes, and Native Hawaiian organizations for the development and implementation of housing policy plans. These plans must increase the housing supply while avoiding resident displacement, increase housing affordability, and reduce barriers to housing development. The amounts provided by the bill are designated as an emergency requirement pursuant to the Statutory Pay-As-You-Go Act of 2010 (PAYGO) and the Senate PAYGO rule. (This excludes the budget effects from being counted for the purposes of enforcing the PAYGO rules.)

In committee Mar 23, 2021 0 co-sponsors
Co-sponsor S 920
In committee · Indiana Senate · Co-sponsor
Affordable and Safe Prescription Drug Importation Act

Affordable and Safe Prescription Drug Importation Act This bill allows expanded importation of eligible prescription drugs and addresses related issues. Current law allows the Department of Health and Human Services (HHS) to authorize the importation of certain eligible prescription drugs from Canada if HHS certifies to Congress that doing so would pose no additional risk to public health and safety and would result in significant cost savings for consumers. The bill removes this certification requirement and requires HHS to issue regulations that permit the importation of qualifying prescription drugs from Canada. After a certain amount of time, HHS may authorize importation from certain other countries if it determines that importation from Canada has resulted in cost savings for consumers and increased access to safe medication. The bill also expands the types of prescription drugs eligible for importation to include, for example, biologics such as insulin. Furthermore, the bill allows individuals to use an eligible licensed foreign pharmacy to fill a U.S.-issued prescription for a qualifying drug for personal use. Currently, an individual seeking to import a prescription drug generally must acquire a waiver from HHS. The bill imposes various requirements related to certification of foreign sellers, labeling of imported drugs, and supply chain security. The bill also (1) prohibits certain acts that discriminate against foreign sellers, such as charging higher prices to foreign sellers than to other sellers in the same country; and (2) imposes criminal penalties for online websites that sell counterfeit drugs or dispense drugs without a required prescription.

In committee Mar 23, 2021 1 co-sponsor
Primary S 889
In committee · Indiana Senate · Lead sponsor
Prescription Drug Monitoring Act of 2021

Prescription Drug Monitoring Act of 2021 This bill imposes, as a condition on certain federal funding for the Prescription Drug Monitoring Program (PDMP), additional notification and reporting requirements concerning prescriptions for potentially addictive drugs. States or territories that receive this funding must require prescribers to consult the PDMP before starting treatment with such drugs, and dispensers to report within 24 hours to the PDMP each time they fill a prescription for such drugs. In addition, the state agency administering a PDMP must analyze reported data for patterns of prescription drug misuse or abuse and provide certain information to prescribers, law enforcement, the public, and other states and territories.

In committee Mar 22, 2021 0 co-sponsors
Co-sponsor S 888
In committee · Indiana Senate · Co-sponsor
CROWN Act of 2021

Creating a Respectful and Open World for Natural Hair Act of 2021 or the CROWN Act of 2021 This bill prohibits discrimination based on a person's hair texture or hairstyle if that style or texture is commonly associated with a particular race or national origin. Specifically, the bill prohibits this type of discrimination against those participating in federally assisted programs, housing programs, public accommodations, and employment. Persons shall not be deprived of equal rights under the law and shall not be subjected to prohibited practices based on their hair texture or style. The bill provides for enforcement procedures under the applicable laws.

In committee Mar 22, 2021 1 co-sponsor
Showing 2,271 to 2,280 of 2,456 bills